{
    "pmcid": "8956255",
    "qa_pairs": {
        "What is the primary target of the SARS-CoV-2-neutralizing nanobodies identified in the study?": [
            "The receptor binding domain (RBD) of the spike protein",
            "The nucleocapsid protein of the virus",
            "The membrane protein of the virus",
            "The envelope protein of the virus"
        ],
        "What method was used to determine the binding affinities and map the binding sites on the RBD for the nanobodies?": [
            "Surface plasmon resonance (SPR) and hydrogen/deuterium exchange mass spectrometry (HDX-MS)",
            "X-ray crystallography and cryo-electron microscopy",
            "ELISA and Western blotting",
            "Flow cytometry and immunoprecipitation"
        ],
        "What strategy was employed to enhance the potency of the nanobodies and limit viral escape?": [
            "Dimerization using sortase A functionalization and click chemistry",
            "Glycosylation modification",
            "PEGylation",
            "Fusion with Fc regions"
        ],
        "Which nanobody construct demonstrated therapeutic efficacy in a transgenic mouse model by reducing viral load and preventing severe disease?": [
            "C7-Alb1",
            "G6",
            "H12",
            "B2"
        ],
        "Which technique was used to visualize the genetic relatedness of nanobodies in the study?": [
            "seqUMAP",
            "t-SNE",
            "PCA (Principal Component Analysis)",
            "Hierarchical clustering"
        ]
    }
}